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Abstract
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 
molecular subtypes. Among these, the HER2-E appear to be associated with higher pathological 
complete response (pCR) rates following anti-HER2-based regimens. Here, we present a meta-
analysis to validate the association of the HER2-E subtype with pCR following anti-HER2-based 
neoadjuvant treatments with or without chemotherapy (CT).
Methods: A systematic literature search was performed in February 2019. The primary objective 
was to compare the association between HER2-E subtype (versus others) and pCR. Selected 
secondary objectives were to compare the association between 1) HER2-E subtype and pCR in 
CT-free studies, 2) HER2-E subtype within hormone receptor (HR)-negative and HR+ disease and 
3) HR-negative disease (versus HR+) and pCR in all patients and within HER2-E subtype. A 
random-effect model was applied. The Higgins’ I2 was used to quantify heterogeneity.
Results: Sixteen studies were included, 5 of which tested CT-free regimens. HER2-E subtype 
was significantly associated with pCR in all patients (odds ratio [OR]=3.50, p<0.001, I2=33%), in 
HR+ (OR=3.61, p<0.001, I2=1%) and HR-negative tumors (OR=2.28, p=0.01, I2=47%). In CT-
free studies, HER2-E subtype was associated with pCR in all patients (OR=5.52, p<0.001, I2=0%) 
and in HR+ disease (OR=4.08, p=0.001, I2=0%). HR-negative status was significantly associated 
with pCR compared to HR+ status in all patients (OR=2.41, p<0.001, I2=30%) and within the 
HER2-E subtype (OR=1.76, p<0.001, I2=0%).
Conclusions: The HER2-E biomarker identifies patients with a higher likelihood of achieving a 
pCR following neoadjuvant anti-HER2-based therapy beyond HR status and CT use. Future trial 
designs to escalate or de-escalate systemic therapy in HER2+ disease should consider this 
genomic biomarker.
Keywords
PAM50; breast cancer; HER2-positive; HER2-enriched; biomarker; pathologic complete response
INTRODUCTION
Breast cancer (BC) with overexpression and/or amplification of the Human Epidermal 
Growth Factor Receptor 2 (HER2-positive) represents 11-30% of all breast tumors1. HER2 
positivity is defined today by immunohistochemistry (IHC) as complete and strong 
membrane staining (i.e. score of 3+) in ≥10% of cancer cells, and/or by in situ 
immunofluorescence (ISH) techniques as amplified using a HER2/CEP17 ratio cutoff of ≥ 
2.0 and an average HER2 gene copy number ≥ 4.0 signals per cell2. This consensus 
definition is based on the methods and cutoffs used over the years in pivotal trials that led to 
the approval of trastuzumab3, pertuzumab4, neratinib5, lapatinib6 and T-DM17 in HER2+ 
breast cancer.
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The current HER2 definition do not sufficiently consider HER2+ disease’s clinical and 
biological heterogeneity. On one hand, high variability in patient’s response and survival 
outcomes following anti-HER2-based therapy is common8,9. On the other hand, high 
biological variability exists within HER2+ disease10–12. For example, all the BC intrinsic 
subtypes [i.e. Luminal A, Luminal B, HER2-enriched (HER2-E) and Basal-like] can be 
identified through gene expression profiling9,10,13. Among them, the HER2-E subtype is the 
most frequent (31-76%), shows the highest levels of ERBB2 mRNA and protein and appears 
to be the subtype with the highest activation of the EGFR-HER2 signaling pathway11,14–31. 
Importantly, these biological entities within HER2+ disease are not fully recapitulated by 
hormone receptor (HR) status since 40% of HER2+/HR+ tumors are HER2-E and 15% of 
HER2+/HR-negative tumors are Basal-like10,11,32.
To date, no biomarker has demonstrated clinical utility in HER2+ early disease beyond 
HER2 and HR status33. However, accumulating evidence supports the clinical validity of 
two biomarkers: intrinsic subtyping and stromal tumor infiltrating-lymphocytes (TILs). In 
particular, either the HER2-E subtype or high TILs appears to be associated with high 
response to anti-HER2-based treatments in the neoadjuvant setting14–31,34,35. From a 
prognostic point of view, however, HER2-E subtype is associated with a worse 
prognosis10,36 whereas TILs are associated with a better survival outcome34,37,38. 
Unfortunately, the majority of these data were derived from retrospective analyses from 
individual clinical trials using baseline tumor samples. In addition, most analyses were 
exploratory and unplanned, and limited by relatively small sample sizes.
To increase the level of evidence of the association of the HER2-E subtype with the response 
to anti-HER2 based neoadjuvant regimens, we decided to review the literature and perform a 
meta-analysis.
MATERIALS AND METHODS
Search strategy and selection criteria
A systematic literature search was performed on 12/February/2019 to identify published 
observational, phase II and phase III (randomized and non-randomized) neoadjuvant clinical 
studies involving anti-HER2-based treatments in HER2+ BC, where the association between 
pathological complete response (pCR) and BC molecular intrinsic subtypes was evaluated. 
The literature search had no time nor language restriction, however, only clinical studies 
involving anti-HER2-based neoadjuvant regimens were included, with or without 
chemotherapy. Additional studies particularly relevant to the topic, for which molecular data 
had not been published but were available at the Translational Genomic and Targeted 
Therapeutics in Solid Tumors laboratory of the IDIBAPS (Barcelona, Spain), were also 
included in the analysis. All pre-clinical studies, phase I trials, non-neoadjuvant trials and 
neoadjuvant trials without anti-HER2 agents were excluded. The recommendations of the 
Cochrane Collaboration44 were followed to identify all relevant studies. For our query, we 
used a combination of disease characteristics, study design, treatment setting and strategies 
or drugs. The full query is reported in the Suppl. Materials. Both full articles and studies 
published in the abstract form were included in the analysis, if odds ratios (OR) data were 
directly available or computable. The search was conducted on the electronic databases 
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Pubmed and Web of Science®, as well as on San Antonio Breast Cancer Symposiums 
(SABCS)’s, American Society of Clinical Oncology (ASCO)’s and European Society of 
Medical Oncology (ESMO)’s annual meetings online archives. Four reviewers (FS, TP, NC 
and CR) independently evaluated whether each selected randomized clinical trials (RCT) 
respected the predetermined criteria, and another reviewer (AP) was consulted in case of 
controversy.
Data extraction and objectives
Details on study design, patient/tumor characteristics, interventions and outcome were 
extracted from each paper. Only the most recent and complete reports were included when 
duplicate publications were identified. Crude odds ratio (OR) for pCR with their 95% 
confidence intervals (CI) were extracted or calculated, when necessary, from each published 
paper or internal datasets. The definition of pCR varied across studies. In 12/16 (75%) 
studies (2,176/2,703 patients with known PAM50 subtype), pCR was defined as the absence 
of invasive neoplastic cells at microscopic examination of the primary tumor at surgery in 
breast and axilla (pCR in-breast and axilla), with remaining in-situ lesions allowed. In 4/16 
(25%) studies (527/2,703 patients with known molecular subtype), pCR was defined as the 
absence of tumor cells only in breast, without considering tumor response in axillary lymph 
nodes (pCR in-breast).
The primary objective was to compare the association between HER2-E subtype (versus 
others) and pCR in all patients. Secondary objectives were to:
1. compare the association between HER2-E subtype (versus others) and pCR in 
CT-free studies;
2. compare the association between HR-negative disease (versus HR+) and pCR in 
all patients;
3. compare the association between HR-negative disease (versus HR+) and pCR 
within HER2-E subtype;
4. compare the association between HER2-E subtype (versus others) and pCR 
within HR+ and HR-negative disease;
5. compare the association between each intrinsic subtype (versus the others) and 
pCR.
Statistical analyses
Since a certain degree of heterogeneity was expected, analyses were performed under the 
Random-Effect Model of DerSimonian and Laird45. Heterogeneity was assessed with 
Higgin’s I2 index46. Pre-planned exploratory subgroup analyses for the primary endpoint 
were conducted, even if heterogeneity was not relevant. Subgroup analyses of interest were: 
1) phase II vs phase III trials, 2) randomized vs. non-randomized trials 3) CT-containing vs. 
CT-free studies 4) pCR in-breast vs pCR in-breast and axilla. For the primary endpoint, to 
assess whether the pooled OR estimates were stable or strongly dependent on one or few 
studies, sensitivity analyses were conducted by interactively recalculating the pooled OR 
estimates after exclusion of each single study. Publication bias was explored through funnel 
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plot visual inspection and the Egger’s linear regression test for funnel plot asymmetry47,48. 
All reported p values were two-sided. All statistical analyses and the generation of forest 
plots were conducted using R and RevMan49,50. The Cochrane risk of bias assessment tool 
was employed to assess the quality of the data obtained and the risk of bias in each study. 
Significance was set at p<0.05, except for Egger’s test, for which significance was set as 
p<0.1, as usual. The project was registered in the PROSPERO online database51, with 
registration number: CRD42019140902.
Assessment of risk of bias
The risk of bias for each trial was assessed by using the criteria outlined in the Cochrane 
Handbook for Systematic Reviews of Interventions44. Each domain related to a risk of bias 
was assessed in each included trial, since there is evidence that these issues are associated 
with biased estimates of treatment effect. The domains were the following: 1) random 
sequence generation; 2) allocation concealment; 3) blinding of participants and personnel; 4) 
blinding of outcome assessment; 5) incomplete outcome data; 6) selective reporting; 7) other 
bias. Review authors’ judgments were categorized as “low risk”, “high risk” or “unclear 
risk” of bias. Internal validity of eligible studies was assessed according to the Cochrane 
Collaboration’s ‘Risk of Bias’ tool in Review Manager50.
RESULTS
Summary of studies and patient characteristics
A total of 16 studies were included (Tables 1 and 2; Supplementary Tables 1 and 2)14–31. 
From Pubmed and Web of Science® online databases, 2,207 studies were extracted and 10 
were included14–18,20–22,24,25,28. From ASCO, ESMO and SABCS online abstracts books, 4 
studies were included19,26,27,30,31. Finally, data from 2 studies (ICO-CLINIC, LPT109096) 
were available at the Translational Genomic and Targeted Therapeutics in Solid Tumors 
laboratory at IDIBAPS (Barcelona, Spain)14,26,31. Some data were also retrieved from later-
published full articles11,52. The selection process is resumed in the PRISMA diagram (Fig. 
1). Overall 5 (31.25%) phase III RCT, 5 (31.25%) phase II RCT, 5 (31.25%) non-
randomized phase II trials and 1 (6.25%) retrospective observational study were included. 
All the articles/abstracts containing molecular results have been published between 2014 and 
2019.
From a total of 3,733 patients, PAM50 intrinsic subtype was available for 2,703 (72.4%) 
patients, while HRs status was known for 3,373 (90.3%) patients. Except for one trial (i.e. 
PerELISA) which enrolled HR+ tumors-only28, the others included both HR+ and HR-
negative tumors. All studies included evaluated anti-HER2-based neoadjuvant regimens with 
or without CT14,23,28,29,53, and included tumor stages II or III, except for the PAMELA trial 
and the retrospective observational study from the Catalan Institute of Oncology and the 
Hospital Clinic of Barcelona (ICO-CLINIC), which allowed stage I disease14,26. Various 
methods for assessing the PAM50 BC intrinsic subtypes were used across all trials (Tables 
1–2), but all were based upon gene expression data14–31.
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Among the studies included, only the PAMELA single arm phase II trial was specifically 
designed to prospectively assess PAM50 intrinsic subtypes and test whether patients with the 
HER2-E subtype benefited more than the other subtypes from a neoadjuvant anti-HER2-
based CT-free regimen14. The other studies evaluated PAM50 as an exploratory retrospective 
analysis; therefore, tumor samples were not always available for all patients included. 
However, samples were always available for at least half of the population enrolled within 
each study (Tables 1–2). pCR rates in HER2-E subtype were higher than nonHER2-E 
subtypes in each study, except in the LPT109096 trial. Individual trials’ results are reported 
in Tables 1 and 2.
pCR and HER2-E subtype
The HER2-E subtype was significantly associated with pCR compared to others (OR=3.50, 
95% CI 2.79 – 4.39, p<0.001, I2=33%, Fig. 2). The funnel plot suggested the absence of 
publication bias (Suppl. Fig. 1), confirmed by a non-significant Egger’s test (p=0.48). The 
influential analysis showed consistent results when omitting a single trial with an I2 range 
varying from 3.4% (omitting the NeoSphere trial)20 to 37.7% (omitting the TBCRC023 
trial)31. Full results of the influential analysis are reported in Table 3. Considering the 
absence of significant heterogeneity, an exploratory, non-preplanned analysis done with the 
fixed-effect model54 was performed with a similar result (OR=3.51, 95% CI: 2.96 – 4.16, 
p<0.001, I2=33%).
There were no statistically significant differences in terms of association with pCR for all 
the subgroups considered for the preplanned sensitivity analyses, namely randomized vs. 
non-randomized studies (p=0.46), phase II vs. phase III studies (p=0.13), CT-containing vs. 
CT-free studies (p=0.30), pCR in-breast vs pCR in-breast+axilla (p=0.32). Compared to 
other intrinsic subtypes, the HER2-E subtype was significantly associated with pCR 
compared to Basal-like (OR=2.50, 95% CI 1.78 – 3.52, p<0.001, I2=0%, Suppl. Fig. 2A), 
Luminal A (OR=4.81, 95% CI 3.16 – 7.33, p<0.001, I2=55%, Suppl. Fig. 2B), Luminal B 
(OR=3.82, 95% CI 2.97 – 4.91, p<0.001, I2=0%, Suppl. Fig. 2C) and Luminal A/B 
(OR=4.36, 95% CI 3.17 – 6.00, p<0.001, I2=52%, Suppl. fig. 2D) subtypes. Other 
comparisons among intrinsic subtypes can be found in the Suppl. Materials.
pCR, HR status and HER2-E subtype
Fifteen of the 16 trials were used to assess the association between HR status and pCR. HR-
negative disease was significantly associated with pCR compared to HR+ disease (OR=2.41, 
95% CI 2.00 – 2.92, p<0.001, I2=30%, Fig. 3A). The inspection of the funnel plot (Suppl. 
Fig. 3), as well as the result of the Egger’s test (p=0.68), did not reveal a significant 
publication bias. The HER2-E subtype was significantly associated with pCR within both 
HR-negative disease (OR=2.28, 95% CI 1.21 – 4.29, p=0.01, I2=47%, Fig. 3B) and HR+ 
disease (OR=3.61, 95% CI 2.61 – 5.00, p<0.001, I2=1%, Fig. 3C). Similar to what was 
observed for the general population, HR-negative disease was significantly associated with 
pCR compared to HR+ disease within the HER2-E subtype (OR=1.76, 95% CI 1.30 – 2.38, 
p<0.001, I2=0%, Fig. 3D).
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pCR, HR status and HER2-E subtype in the absence of CT
A total of 5 studies evaluated dual HER2 blockade in the absence of CT14,20,28,29,31, 
although for one of these (i.e. NeoSphere), data for the CT-free arm were not available 
separately from the other CT-containing arms’ data 20. In CT-free regimens, HER2-E 
subtype was significantly associated with pCR compared to the other subtypes (OR=5.52, 
95% CI 2.89 – 10.54, p<0.001, I2=0%, Fig. 4A), while there was no apparent difference 
between HR-negative vs. HR+ disease (OR=1.49, 95% CI 0 44 – 5.03, p=0.52, I2=76%, Fig. 
4B). When considering HR status, the HER2-E subtype was found to be significantly 
associated with pCR within HR+ disease (OR=4.08, 95% CI: 1.76 – 9.46, p=0.001, I2=0%, 
Suppl. Fig. 4A), but not within HR-negative disease (OR=2.18, 95% CI: 0.66 – 7.26, 
p=0.20, I2=0%, Suppl. Fig. 4B). Conversely, in patients with HER2-E subtype, HR status 
was not significantly associated with pCR (OR=1.30, 95% CI 0.67 – 2.52, p=0.44, I2=0%, 
Suppl. Fig. 5).
Risk of bias analysis
With respect to the risk of bias, as defined by the Cochrane’s manual for systematic 
reviews44, the risk of selection bias for random sequence generation and allocation 
concealments was present in the 6/16 (37.5%) of the studies in both cases, with an unclear 
risk in 1/16 (6.25%) studies included, concerning the random sequence generation selection 
bias (Fig. 5 and Suppl. Fig. 6). The performance bias due to blinding of participants and 
personnel was present in 12/16 (75%) of cases, with an unclear risk in 3/16 (18.75%) of the 
studies included. No detection bias related to the blinding of outcome assessment, attrition 
bias due to incomplete outcome data and selective reporting bias were observed. Concerning 
the last two, an unclear risk was present in 1/16 (6.25%) cases. Finally, we accounted for a 
6.25% high risk of other bias related to the ICO-CLINIC study, due to its retrospective and 
non-trial design.
DISCUSSION
The development of effective drugs against HER2+ BC has been particularly successful in 
the last few years3–7. Since the introduction of trastuzumab3, other effective and tolerable 
anti-HER2 drugs (i.e. lapatinib, pertuzumab, neratinib and T-DM1) have been introduced in 
the metastatic and/or early disease settings, contributing to important improvements in 
survival outcomes8,55. However, HER2+ disease is clinically and biologically heterogeneous 
and not all patients benefit to the same extend from current treatments. Thus, better 
identification of patients using biomarkers should allow the design of prospective trials 
aiming to improve precision medicine in HER2+ BC.
Among the different biomarkers evaluated in HER2+ disease over the last 
decade10,14,21,31,34,35,37,39,40,56, the HER2-E subtype has been proposed to identify patients 
whose HER2+ tumors are HER2 “addicted” (meaning driven primarily by signaling via the 
HER2 pathway). Retrospective analysis of the HER2-E subtype, mostly exploratory and 
unplanned, using baseline tumor samples from individual clinical trials have linked this 
phenotype with high rates of pathological complete response following neoadjuvant anti-
HER2-based therapies14–31. However, to date, no combined analysis or meta-analysis has 
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been performed and analyses within all of those studies were limited by relatively small 
sample sizes. Here, we performed a trial-level meta-analysis of 16 neoadjuvant studies and 
2,703 patients to evaluate the association of the HER2-E subtype with pCR. In particular, we 
confirmed that the HER2-E subtype is a consistent biomarker to identify patients with a 
higher likelihood of achieving a pCR following anti-HER2-based therapy with or without 
cytotoxic therapy. Importantly, the association of the HER2-E subtype with pCR appeared to 
be independent of HR status, which is the only biomarker with clinical utility in HER2+ 
disease. Additionally, our results confirm the ability of HR status to predict pCR by itself 
and within the HER2-E subtype, although we could not demonstrate this in the CT-free 
setting, which had substantially fewer contributing trials.
We adopted pCR as our clinical endpoint for this meta-analysis. This is because numerous 
studies have demonstrated a favorable prognostic role in early stage HER2+ BC56–60 so its 
use as primary endpoint in neoadjuvant trials has been increasing over the years and has also 
been endorsed for regulatory purposes by regulatory agencies such as US Food and Drug 
Administration (FDA), for accelerated approval of neoadjuvant treatments in high risk early-
stage BC61. Furthermore, the FDA recently approved the use of adjuvant T-DM1 (in HER2+ 
BC) or capecitabine (in HER2-negative BC) in case of no achievement of pCR following 
standard neoadjuvant systemic therapy and surgery, making of pCR a fundamental tool in 
therapeutic decision-making in non-metastatic BC for escalating treatment strategies. At the 
same time, there is also an increasing use of pCR as a tool to identify potentially effective 
and safe de-escalating therapeutic approaches in HER2+ BC14,28,29,62. In fact, identification 
of effective de-escalating treatment strategies to spare toxicity and financial costs to patients 
is a main focus of the research community nowadays63,64. In adjuvant setting, several 
prospective trials of early stage HER2+ BC have attempted to demonstrate that de-escalating 
strategies based on a shorter duration of adjuvant trastuzumab provided similar benefits as 
the conventional 1 year; however, the results using non-inferiority trial designs were 
mixed65. On the contrary, a single-arm trial from a single institution (i.e. the APT trial) 
evaluating 12 doses of adjuvant weekly paclitaxel and 1-year of trastuzumab in largely HR+ 
stage I disease significantly impacted on daily clinical practice after showing extraordinary 
DFS and OS rates at 7-years66. In this scenario, at least 3 critical questions remain to be 
answered regarding de-escalation of systemic therapy in early HER2+ disease: 1) who can 
be treated with less or even no adjuvant trastuzumab after surgery? 2) who does not need 
(neo)adjuvant pertuzumab in stage II and III disease? 3) can we decrease the amount of 
chemotherapy? In fact, immunohistochemically HER2+/non-HER2-E tumors might be 
poorly dependent, if not totally independent, from the HER2-signaling pathway and not gain 
any benefit from adjuvant trastuzumab following previous neoadjuvant therapy and surgery. 
At the same time some HER2+ tumors might be “HER2 addicted” enough not to need 
chemotherapy at all or to require a shortened adjuvant trastuzumab duration and/or no 
adjuvant dual blockade therapy. To address these questions, well-designed clinical trials 
integrating clinical variables (such as tumor dimension and axillary nodes involvement), 
response data and biomarkers such as the HER2-E subtype, TILs, intra-tumor 
heterogeneity67 and PIK3CA status are needed.
This meta-analysis has several limitations. First, some secondary end-points were affected 
by discrete levels of heterogeneity (I2>75% and p heterogeneity<0.05, results in Fig. 4B and 
Schettini et al. Page 8













Suppl. Materials). This was mostly attributable to the paucity of molecular data from some 
trials and differences in the effects observed, preventing them from being fully reliable, 
regardless of the analytical model applied. However, this consideration doesn’t apply to the 
main result of the study. Second, although several studies correlated pCR with long-term 
survival outcomes (EFS/DFS and OS) in the context of HER2+ BC56–60, others failed to 
demonstrate its role as an efficient surrogate endpoint for survival68,69. Additionally, there is 
a specific lack of survival data related to intrinsic subtypes within the clinical trials included 
in this study. Therefore, no claims regarding the association of HER2-E with patient’s 
survival outcome can be made based on this meta-analysis. Moreover, 4/16 trials reported 
data regarding in-breast pCR, which has not been recognized by the FDA as a validated 
endpoint for drug approval in neoadjuvant setting61. Third, the methods used to apply the 
PAM50 algorithm varied across trials. For example, 13 studies used the nCounter 
platform14,17,20,22–29,31, 2 studies used RNA-seq data15,18 and 2 studies used microarray-
based data16,21. Finally, we were only able to perform a study-level meta-analysis instead of 
a patient-level meta-analysis, which would have increased precision and homogeneity and 
enabled thorough exploration of potential effect moderators.
To conclude, our results demonstrate that the HER2-E subtype is a consistent biomarker of 
response following neoadjuvant anti-HER2-based regimens, with and without CT and 
beyond HR status. This biomarker, along with TILs and other biomarkers, such as PIK3CA 
mutations39–42, either alone or in combination43, should be routinely incorporated in future 
prospective clinical trials designed to implement strategies to escalate and/or de-escalate 
systemic therapies11,14–31.
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• We correlated the breast cancer intrinsic subtypes with pCR in HER2+ 
disease
• The HER2-E signature was significantly and consistently associated with 
pCR after anti-HER2-based therapy
• The HER2-E subtype was associated with pCR irrespective of hormone 
receptor status
• The HER2-E subtype was associated with pCR also with chemo-free 
neoadjuvant schemes
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Forest Plots comparing the association with pCR between the HER2-E and the other 
intrinsic subtypes in the overall population.
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A-D. Forest Plots comparing the association with pCR between HR-positive and HR-
negative tumors (A) in the overall population; the association with pCR between the HER2-
E and the other intrinsic subtypes within the HR-negative (B) and HR-positive (C) disease, 
and the association of pCR between HR-positive and HR-negative tumors within the HER2-
E subtype (D).
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Forest Plots comparing the association with pCR between the HER2-E and the other 
subtypes (A), and between HR-negative and HR-positive tumors (B) in CT-free trials.
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Risk of bias analysis.
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